Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by ARK Investment Management LLC

ARK Investment Management LLC lowered its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 31.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,530,293 shares of the company’s stock after selling 686,072 shares during the quarter. ARK Investment Management LLC’s holdings in Nurix Therapeutics were worth $28,831,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NRIX. Amalgamated Bank grew its stake in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the period. Quarry LP grew its stake in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after acquiring an additional 2,435 shares during the period. International Assets Investment Management LLC grew its stake in Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the period. Finally, Quest Partners LLC grew its stake in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after acquiring an additional 1,312 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NRIX shares. Stifel Nicolaus lifted their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada raised their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Stephens restated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. BTIG Research started coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Needham & Company LLC decreased their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.81.

Nurix Therapeutics Stock Down 2.3 %

NASDAQ NRIX opened at $16.47 on Wednesday. The business’s fifty day simple moving average is $18.88 and its 200-day simple moving average is $21.96. The firm has a market cap of $1.25 billion, a PE ratio of -5.70 and a beta of 2.14. Nurix Therapeutics, Inc. has a 52 week low of $10.16 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.80% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.